Resumption of spontaneous ovulation · women with polycystic ovary syndrome not actively trying to conceive
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with polycystic ovary syndrome not actively trying to conceive
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in acne severity · women with polycystic ovary syndrome not actively trying to conceive
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in testosterone level (nmol/L) after 6 months' treatment · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Adverse effects · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
DeathClinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Systemic adverse events at · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events ‐ systemic adverse eventsClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ injection site adverse events Clinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse events ‐ injection site adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in dropoutsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Cumulative incidence of herpes zoster at least 3.2 years · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to lower cumulative incidence of herpes zoster at least 3.2 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ death Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Pain · acute non‐specific LBP
It is very uncertain whether exercise therapy changes pain compared with sham/placebo treatment (very low certainty).
1 finding from 1 review